Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04348955
Other study ID # ICO-2019-08
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 7, 2019
Est. completion date May 12, 2020

Study information

Verified date April 2022
Source Institut Cancerologie de l'Ouest
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In spite of progresses made in the medical and nurse announcement (linked to the cancer plan), still a lot of patients fell lost, anxious, especially during the first venue at the hospital day care for their chemotherapy. A longer time is necessary to give them again explanation, to reassure and to listen to them. However, patients are not always in ability to hear due to their psychological status. Young women seem to be more in distress, this is linked to the fear of the disease, the change of their social status and the future of their children. It must be noted that there is an increase of complementary therapies including Touch-Massage. Studies showed its interest on quality of life, anxiety, pain and fatigue. The concept Touch-massage (TM) is defined as a benevolent concern that takes shape through the touch and the sequence of gesture on all or parts of the body. This allows to calm, to relax, to get back into shape, to reassure, to communicate or simply to provide well-being, enjoyable to receive and to practice. This treatment is already offered to the patients at the ICO, in priority while the first course of chemotherapy, but in an informal way. I has been noticed a better-being after the TM, and an increase of demand from the patients. This is why it would be interested to measure the evolution of quality of life of those patients having a chemotherapy for a breast cancer getting or not a TM.


Description:

The participation of the study will be offered to each patient coming for a first course of chemotherapy at the hospital day care for an adjuvant breast cancer. The tracking of the eligible patient will be done during the registration for the schedule. The filling of the questionnaires will occur at the 4 first courses (C1 to C4). The Touch Massage will be offered for the 3 first courses of chemotherapy (C1 to C3). The patient can refuse the TM but she will have to fill the questionnaires. At each moment, the patient can withdraw from the study, the TM can be offered according to the availability of the team and of the choice of the patient during the course of chemotherapy. The questionnaire collection will be done in the patient's room. The quality of life will be evaluated based on the questionnaires EORTC, QLQ C30 and BR23 at C1 and C2. The evaluation of the quality of life at the fourth course will allow to estimate the quality of life after 3 complete courses of chemotherapy. Alongside, the anxiety will be evaluated with the anxiety scale STAI from C1 to C3, when the patient just arrives in the service and before she leaves. At the fourth course, the questionnaire will be filled only at the arrival. After the filling of the questionnaires, the patient will be seen by the medical doctor of the service and the nurse who will take charge of her for the chemotherapy. According the availability of the service, the patient will receive the TM if she wants. A member of the nursing staff formed to the TM (formation dispensed to the ICO) will perform the TM. It will be done during the chemotherapy, during the perfusion of ENDOXAN, which takes an hour. The TM will last 20 minutes. In this way, the TM will not delayed, prolonged and disturb the treatment. At C4, there will not be a TM.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date May 12, 2020
Est. primary completion date May 12, 2020
Accepts healthy volunteers
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - women between 18 and 70 years old - patient with histologically confirmed breast cancer - adjuvant situation - spoken language : french - patient who never had chemotherapy in the past Exclusion Criteria: - Patient unable to sit - Malformation of the back - Wound at the level of the zones to massage - Patient placed under the authority of a tutor - Pregnant patient

Study Design


Intervention

Behavioral:
Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized
Quality of life and anxiety questionnaires before the course of chemotherapy (C1 and C4). Touch-Massage during the course of chemotherapy (from C1 to C3) Anxiety questionnaire at the end of the course of chemotherapy (from C1 to C3)

Locations

Country Name City State
France Insitut de Cancérologie de l'Ouest Angers
France Insitut de Cancérologie de l'Ouest Angers

Sponsors (1)

Lead Sponsor Collaborator
Institut Cancerologie de l'Ouest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the quality of life of patients with an adjuvant breast cancer treated at the ICO depending on the patient benefit or not from the TM during the chemotherapy in a hospital day care Quality of life assessed using QLQ-C30 (Quality of Life of Cancer Patients) questionnaire. It is a general 30-item questionnaire composed by 5 functional scales, 3 symptom scales, a global health status and 5 single items assessing additional symptoms. The scales measures range score from 0 to 100. A high scale score represents a higher response level. For example, a high score for a functional scale represents a healthy level of functioning; a high score for the global health status represents a high quality of life; a high score for the symptom scales represents a high level of symptomatology or problems 90 days
Primary Change from basline quality of life during breast cancer treatment Quality of life assessed using BR23 questionnaire. It is a 23-item questionnaire to measure the functioning and the symptoms associated of breast cancer. The functional dimension is composed of several scales: the reflection of the body, sexual functioning, sexual pleasure and perspective of future. The symptom dimension is composed of different scales such as the systemic therapy, side effects, mammary symptoms, hand symptoms and hair loss. 90 days
Secondary Estimate the prevalence of the patients interested by the TM as part of the adjuvant care of a breast cancer at the ICO site of Angers The prevalence of the number of patients interested by the TM is the ratio between the patients responding "yes" to the question : "would you like to receive a Touch-Massage" and the number of patients included in the study. 90 days
Secondary Evaluate the benefits of the TM on the anxiety Measure the anxiety with the help of the scale of the validated STAI (State Inventory Anxiety). A high score (more than 48 for men and 55 for women) represents a high level of anxiety. 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05941299 - Clinical Trial to Demonstrate the Safety and Performance of REGENERA Breast Implant in 40-70 Years Old Women Affected by Malignant Breast Lesion Treated by Lumpectomy N/A
Completed NCT05812326 - PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer Phase 1/Phase 2
Recruiting NCT04424732 - SBRT for Breast Cancer Oligometastases N/A
Completed NCT03109080 - Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) Phase 1
Recruiting NCT04198727 - Study of the Impact of DPD Activity on the Efficacy of Capecitabine N/A
Completed NCT03525990 - Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients N/A
Recruiting NCT04289805 - Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) Phase 4
Available NCT05134922 - Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009